Importantly, BLM-pretreated B16OVA tumor cells exhibited increased susceptibility to the cytotoxicity of MHC-I–restricted OVA-specific CD8+ T cells (preactivated OT-I T cells) compared with the control group. The gene discussed is CD8A; the disease is neoplasm.